SAN FRANCISCO, July 15, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders' rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial's data and design and, if not, whether the company may have violated the federal securities laws.

globenewswire.com - 2026-07-15 16:02:00

BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.

zacks.com - 2026-07-15 11:55:43

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results and highlight progress on key programs.The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.About Ionis Pharmaceuticals, Inc.For three decades, Ionis has invented me.

businesswire.com - 2026-07-15 07:05:00

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw. com or 646-581-9980, ext. 7980.

globenewswire.com - 2026-07-14 17:00:28

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

globenewswire.com - 2026-07-14 17:00:00

SAN FRANCISCO, July 14, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders' rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial's data and design and, if not, whether the company may have violated the federal securities laws.

globenewswire.com - 2026-07-14 12:17:00

IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.

zacks.com - 2026-07-14 11:06:11

Ionis Pharmaceuticals (NASDAQ: IONS) investors absorbed a >20% share decline after the Phase-3 CARDIO-TTRansform trial missed its primary endpoint. Levi & Korsinsky is investigating potential securities law violations.

globenewswire.com - 2026-07-14 10:20:00

[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranerse

gurufocus.com - 2026-07-14 10:00:00

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease. The data, presented at the Alzheimer's Association International Conference (AAIC) 2026, expand upon previously reported topline results and demonstrate a combination of meaningful clinical effi.

businesswire.com - 2026-07-14 09:16:00

When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.

marketbeat.com - 2026-07-13 12:25:30

NEW YORK--(BUSINESS WIRE)--Shares of Ionis Pharmaceuticals fell more than 20% in the early trading on July 9, 2026, after the Company announced that its late-stage Phase-3 CARDIO-TTRansform trial, partnered with AstraZeneca, failed to meet its primary endpoint. If you purchased IONS securities and suffered a loss, you are encouraged to protect your shareholder rights now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. The CARDIO.

businesswire.com - 2026-07-13 10:00:00

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living with Dravet syndrome, a rare, severe and lifelong neurological disorder. Dravet syndrome typically begins in infancy and is associated with prolonged seizures, developmental delays, cognitive impairments and an increased risk of sudden death. “The first participa.

businesswire.com - 2026-07-13 07:00:00

Shares of Ionis Pharmaceuticals (NASDAQ:IONS | IONS Price Prediction) are down 9% intraday, changing hands near $58.30 after opening the session at $64.27.

247wallst.com - 2026-07-10 15:37:34

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and partner AstraZeneca Plc (NYSE:AZN) said on Thursday that their Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint.

benzinga.com - 2026-07-10 11:30:43

/PRNewswire/ -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) dropped more than 20% pre-market on July 9, 2026, after the Company announced that its

prnewswire.com - 2026-07-10 09:00:00

Ionis Pharmaceuticals told investors its CARDIO-TTRansform program was on track to deliver landmark data -- then the Phase-3 trial missed its primary endpoint. Levi & Korsinsky is investigating.

prnewswire.com - 2026-07-09 20:57:00

AstraZeneca PLC shares fell >6% after Wainua (eplontersen) failed its Phase 3 ATTR-CM trial, missing a major revenue opportunity. The stock of Ionis Pharmaceuticals, Inc., developer of eplontersen and in line for royalties on sales of eplontersen, also fell by >20%. AZN's ambitious $80bn 2030 revenue target now faces a ~$15bn gap by my calculation, but a robust late-stage pipeline and strong oncology division provide resilience.

seekingalpha.com - 2026-07-09 15:58:21

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and partner AstraZeneca Plc (NYSE:AZN) on Thursday said their Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint.

benzinga.com - 2026-07-09 08:09:28

AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.

barrons.com - 2026-07-09 07:38:00

AstraZeneca said ​on Thursday ‌that its drug ​Wainua, ​made in partnership ⁠with ​Ionis , ​failed to meet the ​main ​goal of reducing ‌cardiovascular ⁠deaths and recurring heart ​problems ​in ⁠a late-stage ​trial.

reuters.com - 2026-07-09 02:12:37

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner AstraZeneca today announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to Week 140 compared with placebo. In this contemporary patient population treated with standard of care, includin.

businesswire.com - 2026-07-09 02:00:00

Ionis completes enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions.

zacks.com - 2026-07-07 13:31:04

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the global Phase 3 REVEAL study evaluating obudanersen (ION582), an investigational RNA-targeted medicine for people living with Angelman syndrome (AS), a serious and rare neurodevelopmental disorder associated with significant impairments in communication, physical function and cognition. The pivotal cohort enrolled 136 participants.

businesswire.com - 2026-07-06 07:00:00

Ionis grants Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. commercialization and securing upfront and royalty payments.

zacks.com - 2026-06-26 11:45:30

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript

seekingalpha.com - 2026-06-25 14:32:17

Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market as the first approved treatment for the condition.

zacks.com - 2026-06-25 14:31:03

The U.S. Food and Drug Administration (FDA) approved on Wednesday Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Tryngolza (olezarsen) to treat severe hypertriglyceridemia.

benzinga.com - 2026-06-25 12:25:04

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Recordati (“Recordati”), under which Recordati obtained exclusive rights to develop and commercialize zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), in all countries outside the U.S. Ionis will maintain sole commercial responsibility for zilganersen in the U.S. and will continue to lead development globally. Recordati.

businesswire.com - 2026-06-25 02:59:00

[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZAÂ (olezarsen) a

gurufocus.com - 2026-06-24 15:00:00

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA® (olezarsen) as an adjunct to diet to reduce triglycerides (TG) and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG greater than or equal to 500 mg/dL). TRYNGOLZA is available in a 50 mg or 80 mg dose and is self-administered once monthly via an autoinjector. sHTG is characterized by an increased.

businesswire.com - 2026-06-24 14:37:00

Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-10 13:22:10

[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leade

gurufocus.com - 2026-06-08 08:00:00

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leader, to the Ionis Board of Directors, effective immediately.“We are pleased to welcome Dr. Hantson to the board,” said Joseph Loscalzo, M.D., Ph.D., chairman of the Ionis Board of Directors. “Ludwig's biopharma executive leadership experience will be especially meaningful as Ionis prepares for a steady cadence of new c.

businesswire.com - 2026-06-08 07:00:00

Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.

zacks.com - 2026-06-05 13:05:19

Ionis Pharmaceuticals, Inc. (IONS) Discusses Progress in RNA Therapeutics and Transition to Commercial-Stage Biotechnology Transcript

seekingalpha.com - 2026-06-05 08:12:54

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) will be presented during four oral presentations at upcoming medical conferences. Data will be presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) in New Orleans (June 5-8), the National Lipid Association (NLA) Scientific Sessions in Ch.

businesswire.com - 2026-06-04 07:00:00

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-05-29 12:32:01

Ionis Pharmaceuticals remains a Buy, with a compelling bull case despite a >125% 12-month share price increase. IONS is transitioning from niche indications to multi-billion-dollar markets, leveraging key partnerships and upcoming product launches. Projected 2030 revenues exceed $5bn, driven by Tryngolza, Dawnzera, and significant royalty streams from eplontersen, bepiroversen, and pelacarsen.

seekingalpha.com - 2026-05-28 15:32:56

[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligon

gurufocus.com - 2026-05-28 05:00:00

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). Results from the two Phase 3 trials, B-Well 1 and B-Well 2, were simultaneously published in the New England Journal of Medicine and presented at the European Association for the Study of the Liver (EASL) congress. GSK licensed bepirovirsen from Ionis an.

businesswire.com - 2026-05-28 04:45:00

Ionis Pharmaceuticals NASDAQ: IONS highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets' Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launches into a broader commercial and late-stage development phase.

marketbeat.com - 2026-05-25 20:07:19

Ionis Pharmaceuticals, Inc. (IONS) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-19 10:10:48

Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis Pharmaceuticals NASDAQ: IONS products including TRYNGOLZA, DAWNZERA and WAINUA, as well as Neurocrine Biosciences' commercial and pipeline strategy. Get Ionis Pharmaceuticals alerts:Sign UpIonis Highlights TRYNGOLZA Opportunity in Severe Hypertriglyceridemia Todd Tushla, vice president of investor relations, said Ionis is preparing for a potential June 30 FDA action date for olezarsen in severe hypertriglyceridemia, or sHTG.

marketbeat.com - 2026-05-18 06:05:43

Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.

zacks.com - 2026-05-15 12:31:22

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating diranersen (IONIS-MAPTRx/BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease (AD). The CELIA results provide the first evidence from a randomized Phase 2 study of a tau-directed therapy demonstrating both robust biomarker impac.

businesswire.com - 2026-05-14 07:05:00

Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 17:30:47

GSK partnered with Sino Biopharmaceutical to advance hepatitis B drug bepirovirsen in China while launching its final buyback tranche.

feeds.benzinga.com - 2026-05-11 12:03:51

Analyzing the Impact of Tweedy Browne (Trades, Portfolio)'s Recent 13F Filing Tweedy Browne (Trades, Portfolio) recently submitted the 13F filing for the first

gurufocus.com - 2026-05-06 18:08:00

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4, 2026. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2026, are invited to participate in the virtual Annual Meeting we.

businesswire.com - 2026-05-04 07:05:00